08:15 - 08:45 | New Criteria For MS Diagnosis
Mehran Ghafari

08:45 - 09:15 | Clinical Redflags In MS Diagnosis
Sepideh Paybast

09:15 - 09:45 | MRI In MS :green And Redflags
Mostafa Jafari

09:45 - 10:15 | Differential Diagnosis Of MS
Zahra Shirkhani

10:15 - 10:30 | Q And A

11:00 - 11:20 | Injectables And Teriflunomide
Farhad Golipour

11:20 - 11:40 | DMF And Cladribine
Saeede Mirtooni

11:40 - 12:00 | S1P Modulators
Zohre Abna

12:00 - 12:20 | Anti CD20 Therapies
Masoud Nabavi

12:20 - 12:40 | Natalizumab
Samira Navardi

12:40 - 13:00 | Q And A

14:00 - 14:45 | Women’s Issues In MS
M. Abootorabi

14:45 - 15:15 | Approach To Myelitis
Masoud Ghiasian

15:15 - 15:45 | Approach To Optic Neuritis
Nahid Beladimoghaddam

15:45 - 16:00 | Q And A

11:00 - 11:50 | Advanced MRI In MS Pitfalls In Interpretation Of MRI Findings In MS
Elnaz Asadollahzadeh

11:50 - 12:00 | Q And A

14:00 - 15:00 | Panel : Choose The Right, Win The Fight Choosing The Right Oral Therapy In MS
Samira Navardi , Maryam Poorsadeghfard , Mohammadali Sahraian

15:00 - 15:10 | Introduction And Opening Remarks
Masoud Nabavi

15:10 - 15:20 | Case Presentation 1:Selecting Siponimod In Active SPMS
Maryam Poorsadeghfard

15:20 - 15:30 | Case Presentation 2:Real -World Management Of An Elderly Patient With SPMS
Samane Hosseini

15:30 - 16:00 | Panel : Panel Discussion

16:30 - 17:30 | Mavenclad In Clinical Practice
Maryam Poorsadeghfard

08:00 - 08:15 | Impact Of Exercise On Symptoms, Disease Activity, Progression, And Disability In MS Patients
A. Moghaddam Ahmadi

08:15 - 08:35 | Choosing DMT In RIS And CIS
Behnaz Sedighi

08:35 - 08:55 | Choosing DMT In Comorbidities-consultations
Zahra Hamed

08:55 - 09:15 | Choosing DMT In Pregnancy
Hoda Kamali

09:15 - 09:30 | Choosing DMT In Progressive MS
Nastaran Majdinasab

09:30 - 10:30 | Panel : Choosing DMT In MS
Moderators : Alireza Nikseresht
Panel Members : Mohammad Baghbanian , Abdolreza Naser Moghadasi , Maryam Poorsadeghfard , Vahid Shayegannejad

11:00 - 11:05 | ?
Dr.Farzad Mehrabi

11:05 - 11:20 | ?
Dr. M Motamedi

11:20 - 11:50 | Advances In Multiple Sclerosis Over The Past Year
Mohammadali Sahraian

11:50 - 12:15 | Articles Published By Iranian Researchers During The Last Year
Abdolreza Naser Moghadasi

12:15 - 12:22 | Comparison Of Brain Derived Neurotrophic Factor (BDNF) Plasma Levels In Secondary Progressive Multiple Sclerosis Patients Treated With Anti CD-20 Drugs With Healthy Population
Mahdi Maghbouli

12:22 - 12:29 | Long-term Clinical And Psychological Efficacy And Safety Of Ocrelizumab in People With Multiple Sclerosis: A Real-world Longitudinal Study
Mohammad Yazdan Panah

12:29 - 12:35 | Investigation Of The Effects Of Mesenchymal Stem Cells On Disease Activity Criteria In An Experimental Model Of Experimental Autoimmune Encephalomyelitis (EAE)
Reza Karbalaei

12:35 - 12:50 | Autologous Hematopoietic Stem Cell Transplantation In Multiple Sclerosis: Interim Results From An Iranian Study
Dr.Amirreza Azimi

12:50 - 13:00 | Recognition Of Leading Female Neurologists In MS In Iran

14:00 - 14:20 | Pitfalls In Clinical Differentiation Between Relapsing And Progressive MS
Sareh Shahmohammadi

14:20 - 14:40 | Vaccinations And Infectious Issues In MS
Zahra Nikoo

14:40 - 15:00 | Pitfalls In Interpretation Of OCT, VEP And CSF Findings
Samane Kabiri

15:00 - 16:00 | Panel : Pitfalls In Symptomatic Treatment In MS
Moderators : Ehsan Mohammadianinejad
Panel Members : E. Azimian , Masoud Etemadifar , Fatemeh Gitinavard , E. Koochaki , Ebrahim Koochaki

08:00 - 08:30 | Case 1
Zahra Shirkhani

08:30 - 08:45 | Multiple Sclerosis Presenting As Pseudoneurologic Syndrome- Case Report
Ahmad Chitsaz

08:45 - 09:00 | Tumefactive Or Tumoral Lesion?
Hossein Mojdehipanah

14:00 - 14:50 | OCT
Amin Ahmadi

14:50 - 15:00 | Q And A

15:00 - 15:30 | Surrogate Biomarkers In Multiple Sclerosis: Therapeutic Impact Of High-Efficacy Treatment
Mohammadali Sahraian

15:30 - 16:00 | Ocrelizumab :Latest Updates And Insights
Samira Navardi

16:30 - 17:30 | MS Oral Treatment From Disease Control To Quality Of Life Improvement
Panel Members : Roya Abolfazli , Maryam Poorsadeghfard , Mohammadali Sahraian

17:30 - 18:30 | Efficacy Evidence & Early Initiation PML Risk Mitigation Strategies
Mohammadali Sahraian

08:00 - 08:15 | MS Epidemiology In Iran
Sharareh Eskandarieh

08:15 - 08:35 | NMO And MOGAD:diagnostic Criteria
Roya Abolfazli

08:35 - 08:50 | Principles Of Cell-Based Assays (CBA)
Mostafa Jafari

08:50 - 09:10 | MRI Findings In MS Vs NMO Vs MOGAD
Nafise Mohebi

09:10 - 09:30 | MRI Differential Diagnoses In NMO And MOGAD
Zahra Ebadi

09:30 - 10:30 | Panel : NMO And MOGAD Treatment
Moderators : Fereshte Ashtari
Panel Members : Iman Adibi , Hamidreza Ghalianchi , Masoud Nabavi

11:00 - 11:15 | Case Presentation: Sjögren–Larsson Syndrome
Mohammad Mahdi Nasehi

11:15 - 11:30 | Fulminant Acute Hemorrhagic Leokoencephalitis(Hurst Syndrome)in A 8-year Old Girl
Morteza Heidari

11:30 - 11:50 | Case Presentation: Fanconi Anemia Neuroinflammatory Syndrome
Narges Hashemi

11:50 - 12:00 | Q And A

12:00 - 12:15 | Autoimmune Encephalitis:clinical Presentations
Mahnaz Talebi

12:15 - 12:30 | Autoimmune Encephalitis:diagnosis
Samane Hosseini

12:30 - 12:50 | Autoimmune Encephalitis:treatment
Hormoz Ayromlou

12:50 - 13:00 | Q And A

08:00 - 09:30 |
Abdolreza Naser Moghadasi

09:30 - 10:00 |
Reza Gholamali Zadeh

10:00 - 10:30 |
M. Abootorabi

10:30 - 11:00 |

11:00 - 13:00 |
Ebrahim Koochaki